Kedor-B (02487) announced that the group's pharmaceutical CU-30101 has obtained China's National Medical Products Administration (NMPA) approval for listing application...
According to the announcement by Kedor-B (02487), the group's pharmaceutical CU-30101 has received acceptance for its application for listing permit from the National Medical Products Administration (NMPA) of China.
CU-30101 is a topical lidocaine and prilocaine compound cream used for local anesthesia of skin and superficial surgical procedures. Due to its unique pharmacokinetic properties, the combined formula of lidocaine and prilocaine in CU-30101 can produce rapid and long-lasting anesthesia effect. Lidocaine diffuses faster and wider than prilocaine, while prilocaine is a long-acting aminoester local anesthetic that is more lipophilic than lidocaine and can concentrate in the stratum corneum of the skin. The systemic absorption of anesthetic components is also limited by the cream formulation.
